scholarly article | Q13442814 |
P50 | author | Michael M. Gottesman | Q6832389 |
Rob Robey | Q58798575 | ||
P2093 | author name string | Christopher J Clarke | |
Myles C Cabot | |||
Daniel W Rosenberg | |||
James P Madigan | |||
Joanna E Poprawski | |||
Huakang Huang | |||
P2860 | cites work | The Hallmarks of Cancer | Q221226 |
Gangliosides: Structures, Biosynthesis, Analysis, and Roles in Cancer. | Q39179774 | ||
AKT/PKB Signaling: Navigating the Network | Q39255027 | ||
GCS overexpression is associated with multidrug resistance of human HCT-8 colon cancer cells | Q39378630 | ||
Glucosylceramide synthase protects glioblastoma cells against autophagic and apoptotic death induced by temozolomide and Paclitaxel. | Q39413826 | ||
Sphingolipid abnormalities in cancer multidrug resistance: Chicken or egg? | Q39421907 | ||
Regulation of survivin by PI3K/Akt/p70S6K1 pathway | Q39719614 | ||
Sphingosine kinase isoforms regulate oxaliplatin sensitivity of human colon cancer cells through ceramide accumulation and Akt activation. | Q39880179 | ||
Critical role for lipid raft-associated Src kinases in activation of PI3K-Akt signalling | Q40175298 | ||
Chronic oxaliplatin resistance induces epithelial-to-mesenchymal transition in colorectal cancer cell lines | Q40252973 | ||
Endogenously produced ganglioside GM3 endows etoposide and doxorubicin resistance by up-regulating Bcl-2 expression in 3LL Lewis lung carcinoma cells | Q40298527 | ||
Lack of ceramide generation and altered sphingolipid composition are associated with drug resistance in human ovarian carcinoma cells | Q40339862 | ||
Sphingosine kinase 1 is up-regulated in colon carcinogenesis | Q40345686 | ||
Oxaliplatin, a potent inhibitor of survivin, enhances paclitaxel-induced apoptosis and mitotic catastrophe in colon cancer cells | Q40396941 | ||
Oligonucleotides blocking glucosylceramide synthase expression selectively reverse drug resistance in cancer cells | Q40589199 | ||
Glucosylceramide synthase and glycosphingolipid synthesis | Q41018584 | ||
Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel | Q41144344 | ||
Enhancement of epidermal growth factor signaling and activation of SRC kinase by gangliosides | Q42825899 | ||
Identification of a plasma membrane Raft-associated PKB Ser473 kinase activity that is distinct from ILK and PDK1. | Q44101117 | ||
Altered sphingolipid metabolism in N-(4-hydroxyphenyl)-retinamide-resistant A2780 human ovarian carcinoma cells | Q44251894 | ||
Improved inhibitors of glucosylceramide synthase | Q44295948 | ||
Characterization of malignant colon tumors with 31P nuclear magnetic resonance phospholipid and phosphatic metabolite profiles | Q71066996 | ||
Inhibition of G1/S transition potentiates oxaliplatin-induced cell death in colon cancer cell lines | Q79895102 | ||
An Overview of Sphingolipid Metabolism: From Synthesis to Breakdown | Q24628769 | ||
Tumor-Related Molecular Mechanisms of Oxaliplatin Resistance | Q26799848 | ||
Cell death by mitotic catastrophe: a molecular definition | Q28255830 | ||
Principles of bioactive lipid signalling: lessons from sphingolipids | Q28265743 | ||
Accumulation of glucosylceramides in multidrug-resistant cancer cells | Q28284394 | ||
limmaGUI: a graphical user interface for linear modeling of microarray data | Q33205531 | ||
Overcoming chemotherapy drug resistance by targeting inhibitors of apoptosis proteins (IAPs) | Q33841579 | ||
Ceramide regulates cellular homeostasis via diverse stress signaling pathways | Q34323738 | ||
Survivin may be a Key Target for Oxaliplatin | Q34385251 | ||
Oxaliplatin: a review in the era of molecularly targeted therapy | Q34541434 | ||
Survivin expression and resistance to anticancer treatments: perspectives for new therapeutic interventions. | Q34756476 | ||
Glucosylceramide synthase and apoptosis | Q35047165 | ||
Biosynthesis and degradation of mammalian glycosphingolipids | Q35153204 | ||
Molecular mechanisms of resistance and toxicity associated with platinating agents | Q35758048 | ||
Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes | Q36105474 | ||
Glycosphingolipids and drug resistance. | Q36607613 | ||
Familial adenomatous polyposis is associated with a marked decrease in alkaline sphingomyelinase activity: a key factor to the unrestrained cell proliferation? | Q36619585 | ||
The metabolism and function of sphingolipids and glycosphingolipids. | Q36844738 | ||
Retained platinum uptake and indifference to p53 status make novel transplatinum agents active in platinum-resistant cells compared to cisplatin and oxaliplatin. | Q36920272 | ||
Role for sphingosine kinase 1 in colon carcinogenesis. | Q37072425 | ||
Death through a tragedy: mitotic catastrophe | Q37135368 | ||
Sphingolipids in colon cancer | Q37655806 | ||
Sphingolipid analysis by high performance liquid chromatography-tandem mass spectrometry (HPLC-MS/MS). | Q37797399 | ||
Glucosylceramide in Humans | Q37797414 | ||
Ceramide-orchestrated signalling in cancer cells. | Q38067062 | ||
Sphingolipids: key regulators of apoptosis and pivotal players in cancer drug resistance | Q38195691 | ||
A subset of platinum-containing chemotherapeutic agents kills cells by inducing ribosome biogenesis stress | Q38713515 | ||
Inhibiting glucosylceramide synthase exacerbates cisplatin-induced acute kidney injury | Q38793821 | ||
Inhibition of Glucosylceramide Synthase Sensitizes Head and Neck Cancer to Cisplatin | Q38865121 | ||
Molecular Pathways: The eIF4F Translation Initiation Complex-New Opportunities for Cancer Treatment | Q38993162 | ||
Cancer Statistics, 2017. | Q39038674 | ||
P4510 | describes a project that uses | limma | Q112236343 |
P433 | issue | 2 | |
P921 | main subject | colorectal cancer | Q188874 |
oxaliplatin | Q422327 | ||
ceramides | Q424213 | ||
P304 | page(s) | 111860 | |
P577 | publication date | 2020-01-20 | |
P1433 | published in | Experimental Cell Research | Q1524289 |
P1476 | title | A role for ceramide glycosylation in resistance to oxaliplatin in colorectal cancer | |
P478 | volume | 388 |
Search more.